Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Launched by NOVARTIS PHARMACEUTICALS · Apr 25, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at new treatments for people with moderate to severe atopic dermatitis, which is a chronic skin condition that causes itchy and inflamed skin. The trial aims to test several investigational compounds to see if they are effective and safe for patients. It is not yet recruiting participants, but when it does, it will include individuals aged 6 to 75 who have been diagnosed with atopic dermatitis for at least a year.
To participate, individuals must be willing to sign an informed consent form and have moderate to severe symptoms of atopic dermatitis. However, those with certain medical conditions, such as serious infections, uncontrolled diabetes, or other skin diseases, may not be eligible. Participants can expect to receive treatment and will be monitored throughout the study to ensure their safety. This trial is an important step in finding better options for managing atopic dermatitis, which can significantly impact a person's quality of life.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria of the master protocol:
- • Able and willing to sign the informed consent (IC)
- • Patients with a diagnosis of AD and onset of disease for at least 1 year
- • Moderate to severe AD
- Key Exclusion Criteria of the master protocol:
- • Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
- • Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
- • Participant with any other active inflammatory skin disease
- • Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
- • Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma)
- • Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Troy, Michigan, United States
Houston, Texas, United States
Atlanta, Georgia, United States
Santa Monica, California, United States
Saint Joseph, Missouri, United States
San Antonio, Texas, United States
Santa Ana, California, United States
Miami, Florida, United States
Louisville, Kentucky, United States
Brighton, Massachusetts, United States
Troy, Michigan, United States
Arlington, Texas, United States
Birmingham, Alabama, United States
Macon, Georgia, United States
Hamilton, Ontario, Canada
Los Angeles, California, United States
Cypress, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported